Advanced Glioma Panel (FISH, NGS & MGMT Methylation) near me in New Delhi
Understanding Advanced Glioma Panel (FISH, NGS & MGMT Methylation) in New Delhi
What is Advanced Glioma Panel (FISH, NGS & MGMT Methylation) in New Delhi?
The Glioma gene panel is a cutting-edge next-generation sequencing tool designed to potentially offer significant treatment advantages to patients with glioma, a type of brain cancer. This panel meticulously examines 7 pivotal genes associated with glioma, including ATRX, BRAF, TP53, IDH1, IDH2, H3-3A, and TERT, seeking out various single nucleotide variants (SNVs) and insertions/deletions (InDels). With a minimum sequencing depth of 250X on a validated Illumina platform, this panel ensures robust and reliable results. The identified genetic variations are meticulously annotated using an in-house pipeline, and reportable genomic alterations are prioritized and classified in accordance with AMP-ASCO-CAP guidelines, offering invaluable insights for personalized treatment strategies.
In the realm of glioma research, FISH has been pivotal in identifying the 1p/19q co-deletion, a well-studied marker in oligodendroglioma. This genetic alteration serves as an early diagnostic indicator and is associated with improved prognosis and treatment response. The presence of 1p deletion and combined 1p/19q deletion guides therapeutic decisions, while sole 19q loss lacks predictive value for survival or treatment response.
Glioblastoma, the most prevalent and aggressive primary brain tumor, afflicts a relatively small portion of the population, comprising just two to three cases per 100,000 individuals in Europe and North America.Sadly, prognosis for glioblastoma patients is grim, with a median survival rate of approximately 14 months. Treatment options often include the use of alkylating agents like Temador (temozolomide). Promoter methylation-induced epigenetic silencing of the MGMT DNA-repair gene, a crucial determinant in DNA repair, has shown promise in extending survival rates among glioblastoma patients treated with temozolomide. As such, evaluating the promoter methylation status of the MGMT gene has become an integral component of patient molecular profiling.
Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.